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Polymorphisms in the ficolin 1 gene (FCN1) are associated with
susceptibility to the development of rheumatoid arthritis
B. Vander Cruyssen1*, L. Nuytinck2*, L. Boullart3, D. Elewaut1, W. Waegeman3, M. Van Thielen2,
E. De Meester2, K. Lebeer2, R. Rossau2 and F. De Keyser1
Objectives. We investigated the possible association of rheumatoid arthritis (RA) with single nucleotide polymorphisms (SNP) within the
ficolin (FCN) genes. Two SNPs in the FCN1 gene, four SNPs in the FCN2 gene and one SNP in the FCN3 gene were studied.
Methods. The SNPs within the FCN genes were detected by an experimental INNO-LiPA methodology (Innogenetics, Belgium) in
a population consisting of 338 RA patients and 595 controls. The significant SNPs were further evaluated in two subpopulations and related
to carriage of the human leukocyte antigen-shared epitope (HLA-SE), rheumatoid factor (RF) and the presence of anti-citrullinated protein/
peptide antibodies (ACPA).
Results. Two SNPs in the FCN1 gene were significantly associated with RA: the A allele rs2989727 was significantly increased in RA
patients (67%) compared with controls (60%) (P¼ 0.002). Also, the frequency of the G allele of rs1071583 was increased in RA patients
(68%) compared with controls (61%) (P¼ 0.003). Analysis of agreement between SNPs suggested strong linkage between rs2989727 and
rs1071583. Carriage of a FCN1 SNP was independent of carriage of the HLA-SE, RF status and ACPA positivity.
Conclusions. We describe two linked SNPs in the FCN1 gene that are associated with the development of RA.
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Introduction
The lectin pathway of complement activation is a key mechanism
for the mammalian acute phase response to infection and involves
carbohydrate recognition by mannose-binding lectin (MBL) and
ficolins. The major role of these pattern-recognition molecules
(PRMs) is related to the first-line defence against potential
pathogens by recognition of a specific spectrum of glycoproteins
that is crucial in maintaining the self vs non-self discrimination.
Besides this, some of the PRMs may also exhibit endogenous
functions in homeostasis including the removal of apoptotic
cells [1].
So far, three different ficolin proteins have been characterized
in human, each encoded by a separate gene. L-ficolin (also known
as ficoline/P35 or hucolin) is encoded by the FCN2 gene [9q34.3].
H-ficolin (Hakata Ag) is encoded by the FCN3 gene localized on
chromosome 1 and is, together with L-ficolin, secreted in the
serum [2]. The third ficolin (M-ficolin) is encoded by the FCN1
gene located also on chromosome 9q34. Little is known about
M-ficolin, but Liu et al. [3] proved that M-ficolin is a secretory
protein from neutrophils and monocytes in peripheral blood and
type II alveolar epithelial cells. Especially, L-ficolin binds to
clinically important micro-organisms while H-ficolin mainly
binds N-acetylglucosamine (GlcNAc) and N-acetylgalactosamine.
M-ficolin binds GlcNAc bearing neoglycoproteins, N-acetylga-
lactosamine and sialyl-N-acetyllactosamine, suggesting recogni-
tion of microbial carbohydrate residues. It has also been
demonstrated that each of the ficolin types act by activation of
the lectin pathway to exert their innate immunity capacities [2–6].
The aims of the present study were to investigate whether there
is an association of the development of rheumatoid arthritis (RA)
with polymorphisms in any of the three described FCN genes.
We also evaluated dependency with three other RA-associated
biomarkers: carriage of the human leukocyte antigen-shared
epitope (HLA-SE), the presence of anti-citrullinated protein/
peptide antibodies (ACPAs) and rheumatoid factor (RF).
Patients and methods
Patients
The study sample (338 RA patients and 595 controls) was derived
from two populations.
Population 1 (pop1) consisted of 194 patients with long-
standing RA (median disease duration of more than 9 yrs).
Radiological and serological data of these patients have pre-
viously been described [7, 8]. Those RA patients were compared
with a control population of 205 healthy individuals.
Population 2 (pop2) was derived from a consecutive cohort of
1003 patients with a new diagnostic problem, with RA in the
differential diagnosis [9, 10]. After 1 yr, patients were classified
as RA (n¼ 144) and RA was excluded in 629 non-RA patients.
Serological data of this cohort were previously described. All RA
patients and a random sample of 390 non-RA patients were used
in the current study. Serum antibody results could be obtained in
150 RA patients of pop1 and in 520 patients (including 142 RA
patients and 378 non-RA patients) of pop2. All RA patients
fulfilled the ACR classification criteria for RA [11].
All participants gave informed consent and the study was
approved by the local ethical committee.
FCN determination
Several DNA variants, both in coding and non-coding sequences,
were analysed.
FCN1. A G>A variant at position 1981 in the promotor
region (rs2989727) and a A>G variant at position 7919 in exon 9
(rs1071583).
FCN2. A A>C variant at position 64 (rs7865453), an A>G
variant in position 4 (ss32469537) of the promoter and in exon 8
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a C>T change at position 6424 and a G>T change in position
6359 (ss32469544).
FCN3. An SNP localized in IVS5 at position 3836 [C>G
(rs3813800)].
Genotyping was carried out by a multi-parameter assay
allowing simultaneous detection of the relevant DNA variants in
the three FCN genes using reverse-hybridization technology
(Innogenetics). Briefly, specific probes designed to hybridize
with their complementary sequences amplified from the target
DNA are coated as dots on nitrocellulose strips. The hybridized
probes are visualized as coloured dots and can be interpreted
visually. Primers were developed for selective amplification of the
relevant genomic DNA sequences.
Detection of autoantibodies
RF was determined by the latex fixation test (Difco Lab, Detroit,
MI, USA). A cut-off at a 95% specificity level (25U/m,
sensitivity¼ 45%) was previously defined [7].
ACPAs were detected by a research line immunoassay (LIA)
containing the synthetic citrullinated peptide referred to as pepA
(INNO-LIATM RA, Innogenetics) [7, 10, 12]. This test had a
specificity of 98.5% and a sensitivity of 63.6% in an independent
cohort [7].
HLA-SE (HLA-shared epitope) typing by INNO-LiPA
(line probe assay) technology
DNA was extracted from whole blood samples and amplified
using the INNO-LiPA HLA-DRB1 or -DRB decoder amplifica-
tion kits (Innogenetics). HLA typing was performed with the
INNO-LiPA HLA-DRB1 or -DRB decoder kits (Innogenetics),
according to the manufacturer’s instructions. The amino acid
sequences QRRAA, QKRAA and RRRAA at positions 70–74
constitute the RA HLA-SE sequence. Patients were classified
into two groups according to the inheritance of zero vs one or two
copies of the HLA-SE.
Statistical methods
Odds ratios (ORs), 95% confidence intervals (CIs) and chi-square
statistics or Fisher exact tests were calculated in 2 2 tables.
Gamma with its 95% CI, as a measure of ordinal correlation,
was calculated in NM tables. Logistic regression models were fit
and predicted probability plots were calculated as previously
described [9]. Dependency between markers was evaluated in the
pooled cohort by calculating a common OR (Mantel–Haenszel
common OR controlled for diagnosis) and Mann–Whitney testing
for continuous parameters. The Hardy–Weinberg equilibrium was
evaluated in the control populations. Analyses were performed
using SPSS 12.0 (Chicago, IL, USA). A P-value of <0.05 was
considered as statistical significant except for the single nucleotide
polymorphism (SNP) selection, where a P-value of <0.007 was
used as a way to handle multiple comparisons. Given the 338 RA
patients and 595 controls, ¼ 0.007, this study had sufficient
power (¼ 0.8) to detect ORs of less than 1.8 for threats with a
prevalence of <0.8 in controls.
Results
Selection of the associated SNPs
For the selection of the significantly associated SNPs, allele
frequencies, allelic ORs and P-values were calculated in the pooled
population (Table 1). The pre-set significance level for SNP
selection resulted in a selection of two SNPs in the FCN1 gene: the
FCN1 rs2989727 and the FCN1 rs1071583 SNP. Further analysis
of controls suggested Hardy–Weinberg equilibrium was present
for all SNPs.
Further analysis of the FCN1 genotypes
Carriage of at least one A allele of rs2989727 was associated with
RA [OR¼ 2.23 (1.22–4.06) in pop1; OR¼ 2.40 (1.23–4.68) in pop2;
OR¼ 2.24 (1.45–3.46), P< 0.001 overall] (Table 2). Carriage of
at least one G allele of rs1071583 was associated with RA
[OR¼2.08 (1.14–3.81) in pop1 and OR¼ 1.92 (1–3.68) in pop2;
OR¼ 1.94 (1.257–3.00), P¼ 0.002 overall] (Table 2). Analysis of
agreement between SNPs suggested linkage between rs2989727
and rs1071583 in both populations ( ¼ 0.999, P< 0.001).
Independency of the FCN1 SNPs and the HLA-SE,
RF and ACPA
No dependency between the HLA-SE and carriage of the
two FCN1 SNPs could be observed [common OR¼ 0.965
(0.658–1.416) and 0.976 (0.660–1.443)]. Similarly, no dependency
of FCN1 carriage and ACPA [common OR¼ 1.056 (0.496–2.251)
and 1.149 (0.544–2.427)] or the RF [common OR¼ 1.264
(0.662–2.412) and 1.020 (0.533–1.951)] could be demonstrated.
TABLE 1. Allele frequencies and allelic ORs in the pooled population
FCN1 FCN2 FCN3
9q34 9q34 1p35.3
rs2989727 rs1071583 (Prom2)rs7865453 (Prom3) -4AtoG T236M rs7851696 rs3813800
Promoter Exon 9 Promoter Promoter Exon 8 Exon 8 IVS5
G/A A/G A/C A/G C/T G/T C/G
RA patients (population1) Allele 1 0.33 0.31 0.91 0.71 0.70 0.91 1.00
Allele 2 0.67 0.69 0.09 0.29 0.30 0.09 0.00
Controls (population 1) Allele 1 0.42 0.41 0.85 0.78 0.77 0.84 0.98
Allele 2 0.58 0.59 0.15 0.22 0.23 0.16 0.02
RA patients (population 2) Allele 1 0.33 0.33 0.91 0.72 0.68 0.89 1.00
Allele 2 0.67 0.67 0.09 0.28 0.32 0.11 0.00
Controls (population 2) Allele 1 0.39 0.38 0.89 0.73 0.73 0.89 1.00
Allele 2 0.61 0.62 0.11 0.27 0.27 0.11 0.00
RA patients (pooled) Allele 1 0.33 0.32 0.91 0.71 0.69 0.90 1.00
Allele 2 0.67 0.68 0.09 0.29 0.31 0.10 0.00
Controls (pooled) Allele 1 0.40 0.39 0.88 0.74 0.74 0.87 0.99
Allele 2 0.60 0.61 0.12 0.26 0.26 0.13 0.01
Pooled OR
(95% CI)
1.37
(1.12–1.67)
1.36
(1.11–1.66)
0.72
(0.53–0.99)
1.16
(1.04–0.94)
1.28
(1.01–1.14)
0.75
(0.55–1.01)
0.18
(0.02–1.39)
P-value 0.002 0.003 0.043 0.176 0.019 0.059 0.017
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Potential additional value of FCN1 testing to HLA-SE
testing or serological testing in a prediction model
for RA in pop2
Logistic regression demonstrated that FCN1 testing contributed
independently to HLA-SE testing in predicting RA [OR¼ 2.383
(95% CI 1.451–3.912, P¼ 0.001) for carriage of the A variant of
the rs2989727 SNP and OR¼ 2.05 (95% CI 1.252–3.353,
P¼ 0.004) for carriage of the G variant of the rs1071583 SNP.
Similarly, FCN1 testing contributed independently to serological
testing (ACPA positivity and RF as a continuous variable)
OR¼ 2.581 (95% CI 1.289–5.166, P¼ 0.007) for carriage of
the A variant of the rs2989727 SNP and OR¼ 2.307 (95% CI
1.144–4.655, P¼ 0.020) for carriage of the G variant of the
rs1071583 SNP] (Figs 1 and 2). Interaction terms were non-
significant and removed from the models.
Discussion
We describe for the first time an association between carriage of a
SNP in the FCN1 gene and the susceptibility for RA: the G/A
variant of the rs2989727 SNP and the A/G variant of the
rs1071583 SNP. Seven candidate SNPs in three different FCN
genes were studied in a population of 338 RA and 595 controls,
allowing selecting of two FCN1 SNPs. This population consisted
of two subpopulations and the similar ORs demonstrated in
both subpopulations increase the robustness of our findings.
However, further confirmation of these associations is needed,
especially in populations with different genetic backgrounds.
We also demonstrated that carriage of a FCN1 SNP is
independent of carriage of the HLA-SE, RF and ACPA positivity.
Although the ORs were rather small to make the test useful as
a diagnostic tool for clinical practice, the independency with the
HLA-SE and the RA-associated serum markers triggered to
explore a multi-parameter prediction model. Figures 1 and 2 show
that FCN1 determination has a significant additional value to
HLA-SE or combined ACPA and RF testing. The figures suggest
that the additional positive predictive value of carriage of the
A variant of the rs2989727 SNP or the G variant of the rs1071583
SNP is limited but that the absence of the A variant of the
TABLE 2. Gene frequencies of the 2 FCN1 SNPs
Genotype rs2989727 OR (GGvsAG/AA) Genotype rs1071583 OR (AA vs AG/GG)
Population 1 RA GG 0.09 2.23 (1.22–4.06) AA 0.09 2.08(1.14–3.81)
AG 0.48 AG 0.44
AA 0.43 GG 0.46
Control GG 0.19 AA 0.18
AG 0.47 AG 0.47
AA 0.35 GG 0.36
Population 2 RA GG 0.08 2.40(1.23–4.68) AA 0.09 1.92(1.00–3.68)
AG 0.49 AG 0.48
AA 0.43 GG 0.43
Control GG 0.17 AA 0.15
AG 0.44 AG 0.45
AA 0.38 GG 0.40
Overall RA GG 0.09 2.24 (1.45–3.46) AA 0.09 1.94 (1.257–3.00)
AG 0.48 AG 0.46
AA 0.43 GG 0.45
Control GG 0.18 AA 0.16
AG 0.45 AG 0.46
AA 0.37 GG 0.38
FIG. 1. Probability for RA in the function of the HLA-SE and FCN1 status. The black
bars indicate the overall probability for RA in function of the HLA-SE status.
The other bars (red and blue in the online version) indicate the eventual added
value of FCN1 testing to HLA testing. The figures for the FCNrs rs2989727 or the
FCN1 rs1071583 were very similar. The probability for RA was adjusted for the
a priori change for RA given in [9].
FIG. 2. Plots of the predicted probabilities in function of RF titres, ACPA testing and
FCN1 testing. The black line indicates the added value of ACPA testing to RF
testing as already shown in [9]. The other lines (red and blue in the online version)
indicate the eventual added value of FCN1 testing to combined RF and ACPA
testing. The figures for the FCNrs rs2989727 or the FCN1 rs1071583 were
almost identical. Dashed lines indicate ACPA negativity, full lines indicate ACPA
positivity. The predicted probability plots were calculated by means of logistic
regression.
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rs2989727 SNP or the G variant of the rs1071583 SNP has some
additional value to exclude the diagnosis of RA.
The physiological meaning of our findings remains speculative,
as little is known about the role of M-ficolins [3, 13]. One of the
key characteristics of the PRMs in innate immunity lies in the
first line defence, in particular, the specific recognition of invading
micro-organisms and the discrimination between self and non-self.
One can hypothesize that the DNA variations might result in an
altered capacity to recognize self and non-self. Other contributing
mechanisms may be related to the capacity of clearing apoptotic
cells [3, 13].
To conclude, we describe two linked SNPs in the FCN1 gene
that are associated with the development of RA.
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Rheumatology key messages
 Two linked SNPs in the FCN1 gene are associated with RA.
 FCN1 SNPs are independent from RF, anti-CCP and the HLA-SE.
 FCNI SNPs can be used in the prediction models for RA.
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